ºñ¼Ò¼¼Æ÷Æó¾Ï ȯÀÚ¿¡¼ Cisplatin°ú Vinorelbine º¹ÇÕÈÇпä¹ýÀÇ À¯¿ë¼º
Combination Chemotherapy with Cisplatin and Vinorelbine in Patients with Non-Small-Cell Lung Cancer
´ëÇѾÏÇÐȸÁö 2000³â 32±Ç 5È£ p.911 ~ p.917
±è±â¿ø:Kim Kee-Won
¹Ú¼®¿µ:Park Suk-Young/¼Áö¿ø:Suhr Ji-Won/±è½ÂÁØ:Kim Seung-Joon/¾çµ¿Çå:Yang Dong-Hoen/ÀÌÀºÈñ:Lee Eun-Hee/ÀÌ°æ½Ä:Lee Kyung-Shick
Abstract
Purpose: To determine the therapeutic effect and toxicities of cisplatin and vinorelbine combination chemotherapy in patients with inoperable non-small-cell lung cancer. Materials and Methods: Between Jan 1998 and Dec 1999, 28 patients with inoperable non- small-cell lung cancer were treated with cisplatin and vinorelbine combination chemotherapy as induction treatment. A combination of vinorelbine 25 mg/m2 day 1,8 and cisplatin 60 mg/m2 day 1 were giv0n and repeated every 3 weeks. Then we assessed response and toxicity according to WHO grades. Results: According to response criteria, there were 1 complete response, 12 partial response (42.9%), 12 stable disease (42.9%), and 3 progression (10.7%). The median survival was 12 months. According to toxicity grades, 24 grade 3 myelosuppression (24.7%), 12 grade 4 myelosuppression (10.7%), 6 grade 3 and 4 constipation (6.1%), and mild 7 (7.2%) thrombophlebitis were experienced in evaluable 97 cycles. There was no other clinically severe toxicity. Conclusion: These results suggest that combination chemotherapy with cisplatin and vinorelbine in patients with inoperable non-small-cell lung cancer was effective and safe.
Å°¿öµå
Non-small-cell lung cancer, Chemotherapy, Vinorelbine, Cisplatin,
KMID :
0360320000320050911
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
Combination chemotherapy with cisplatin and vinorelbine in patients with inoperable non-small-cell lung cancer was effective and safe.